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Abstract
Background: The co-inhibitory receptor Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) attenuates immune responses and
prevent autoimmunity, however, tumors exploit this pathway to evade the host T-cell response. The T-cell co-stimulatory
receptor 4-1BB is transiently upregulated on T-cells following activation and increases their proliferation and inflammatory
cytokine production when engaged. Antibodies which block CTLA-4 or which activate 4-1BB can promote the rejection of
some murine tumors, but fail to cure poorly immunogenic tumors like B16 melanoma as single agents.
Methodology/Principal Findings: We find that combining aCTLA-4 and a4-1BB antibodies in the context of a Flt3-ligand,
but not a GM-CSF, based B16 melanoma vaccine promoted synergistic levels of tumor rejection. 4-1BB activation elicited
strong infiltration of CD8+ T-cells into the tumor and drove the proliferation of these cells, while CTLA-4 blockade did the
same for CD4+ effector T-cells. Anti-4-1BB also depressed regulatory T-cell infiltration of tumors. 4-1BB activation strongly
stimulated inflammatory cytokine production in the vaccine and tumor draining lymph nodes and in the tumor itself. The
addition of CTLA-4 blockade further increased IFN-c production from CD4+ effector T-cells in the vaccine draining node and
the tumor. Anti 4-1BB treatment, with or without CTLA-4 blockade, induced approximately 75% of CD8+ and 45% of CD4+
effector T-cells in the tumor to express the killer cell lectin-like receptor G1 (KLRG1). Tumors treated with combination
antibody therapy showed 1.7-fold greater infiltration by these KLRG1+CD4+ effector T-cells than did those treated with a4-
1BB alone.
Conclusions/Significance: This study shows that combining T-cell co-inhibitory blockade with aCTLA-4 and active co-
stimulation with a4-1BB promotes rejection of B16 melanoma in the context of a suitable vaccine. In addition, we identify
KLRG1 as a useful marker for monitoring the anti-tumor immune response elicited by this therapy. These findings should aid
in the design of future trials for the immunotherapy of melanoma.
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Introduction
The co-inhibitory receptor Cytotoxic T-Lymphocyte Antigen
4 (CTLA-4) is induced on T-cells shortly after activation and
functions to attenuate their proliferation, IL-2 production, and
contact time with antigen presenting cells (APC) [1,2]. Also,
CTLA-4 appears to support the function of the regulatory T-cell
(Treg) compartment [3]. Antibody blockade of CTLA-4 removes
these suppressive signals and allows tumor-specific T-cells which
would otherwise be anergized to expand and continue to
perform effector functions. Previously, we have shown that the
therapeutic efficacy of CTLA-4 blockade against poorly
immunogenic tumors like B16 melanoma is strongly enhanced
by co-administration of an autologous tumor vaccine expressing
either the cytokine Granulocyte-macrophage colony-stimulating
factor (GM-CSF) or FMS-like tyrosine kinase 3 ligand (Flt3-
ligand) [4,5].
4-1BB (CD137) belongs to the Tumor Necrosis Factor
Receptor (TNFR) superfamily and is transiently upregulated on
both CD4+ and CD8+ T-cells following activation [6]. 4-1BB
ligation is known to co-stimulate CD8+ T-cells increasing their
proliferation, TH1 cytokine production, and survival [7]. A
majority of Tregs express 4-1BB, but it remains unclear whether
agonist antibody treatment exerts a pro- or anti-suppressive effect
on these cells [8,9,10,11]. In immunotherapy studies, 4-1BB
antibodies can enhance tumor rejection, increase tumor-specific
cytotoxicity, and may render effector T-cells resistant to Treg
suppression [10,12,13,14,15]. The mechanisms underlying many
of these observed anti-tumor effects, however, remain to be
elucidated.
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19499Prior studies have shown that agonistic 4-1BB antibodies with or
without CTLA-4 blockade can promote the rejection of some
murine tumors and ameliorate auto-immune toxicity; however,
poorly immunogenic tumors such as B16 melanoma do not
respond to antibody therapy alone [10,14]. We hypothesized that
increasing the tumor-specific T-cell frequency through vaccination
would allow us to better observe the interaction between 4-1BB
activation and CTLA-4 blockade in the B16 melanoma system.
We found that a4-1BB and aCTLA-4 synergized in rejecting
pre-implanted B16 melanomas in conjunction with a B16-Flt3-
ligand (FVAX) but not a B16-GMCSF (GVAX) vaccine.
Combination therapy yielded highly advantageous ratios of
intra-tumoral CD8+ and CD4+ effector T-cells relative to Tregs
which often correlates with rejection in this system [4,16]. 4-1BB
agonist antibody promoted very high levels of both peripheral
and intra-tumoral inflammatory cytokine production; however,
the addition of CTLA-4 blockade strongly augmented IFN-c
production from CD4+ effector cells. Likewise, aCTLA-4 played
a critical role in allowing proliferation of tumor infiltrating CD4+
effectors.
4-1BB agonist antibody treatment induced widespread expres-
sion of the molecule killer cell lectin-like receptor subfamily G
member 1 (KLRG1) as well as the co-inhibitory receptor
programmed death 1 (PD-1) on tumor-infiltrating CD8+ and
CD4+ effector T-cells. We observed the highest numbers of these
KLRG1+ effector T-cells in the tumors of mice receiving
combination CTLA-4 blockade and 4-1BB agonist antibody
suggesting a positive correlation with therapeutic outcome.
By combining T-cell co-inhibitory blockade with co-stimulatory
activation, we were able to induce rejection of poorly immuno-
genic B16 melanoma tumors. Also, we have characterized the
cellular and molecular mechanisms driving this response further
clarifying the basic processes necessary to achieve immune-
mediated tumor rejection.
Results
4-1BB agonist antibody treatment cooperates with CTLA-
4 blockade and B16-Flt3-ligand vaccination to promote
B16 melanoma rejection
Mice were challenged with B16-BL6 melanoma and vaccinated
on days 3, 6, and 9 with a4-1BB and/or aCTLA-4 in addition to
either GVAX, FVAX, or no vaccine. As others have seen in the
B16-F10 model, we observed no curative effect of the antibodies
withoutcellularvaccination(FigureS1)[10,14].Whenadministered
with FVAX, combination co-stimulatory modulation promoted
rejection in57% ofB16melanomachallengedmiceversus20% and
13% for aCTLA-4 and a4-1BB alone (Figure 1A). In the case of
GVAX, however, combination therapy with aCTLA-4 and a4-1BB
was no better than aCTLA-4 alone (Figure 1B).
Combination aCTLA-4 and a4-1BB therapy strongly
increases both CD8+/Treg and CD4+ effector T-cell/Treg
ratios within the tumor
To understand the apparent synergy between CTLA-4
blockade and 4-1BB activation in the context of our Flt3-ligand
Figure 1. Anti-CTLA-4 and a4-1BB synergize in the context of FVAX. Kaplan-Meier survival curves for mice challenged with 2.5610
4 B16-BL6
cells and vaccinated on days 3, 6 and 9 with 1610
6 of A) FVAX or B) GVAX intra-dermally and the indicated antibody or combination intra-
peritoneally. Lack of survival was defined as death or tumor size .1000 mm
3. Each curve represents 3 independent experiments of 10 mice per
group. P values were calculated using the Log-rank (Mantel-Cox) test (* - p#0.05, ** - p#0.01, ***-p,0.001).
doi:10.1371/journal.pone.0019499.g001
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T-cell infiltration of tumor in this background. 4-1BB activation
promoted very strong CD8 infiltration of B16 melanoma, but in
doing so depressed the relative fraction of CD4+ effector cells
(Figure 2A and B). In terms of absolute T-cell numbers, the CD8
T-cell density increased while the CD4 effector T-cell levels were
unchanged (Figure S2A and B). In contrast to a4-1BB, blockade
of CTLA-4 increased both the TIL fraction and absolute
numbers of CD4+ effector T-cells infiltrating the tumors.
Combination therapy with both antibodies benefits from the
highly elevated CD8+ infiltration evoked by a4-1BB, comple-
mented by the CD4+ effector T-cell infiltration elicited by
aCTLA-4.
While both co-stimulatory modulating antibodies depressed the
fraction of Tregs in B16 melanoma TIL (Figure 2C), CTLA-4
blockade increased absolute numbers of Tregs in the tumor at day
14, whereas a4-1BB did not (Figure S2C). Together, aCTLA-4
and a4-1BB not only diminish the Treg fraction of TIL, but also
reduce the intra-tumoral numbers of Tregs to those achieved with
a4-1BB alone.
By increasing CD8 infiltration and attenuating regulatory T-cell
accumulation, combination aCTLA-4 and a4-1BB treatment
strongly increased intra-tumoral CD8 to Treg ratios (Figure 2D).
CD4 effector to Treg ratios in the tumor were also elevated in
combination therapy, largely due to the effects of CTLA-4
blockade in promoting increased CD4 infiltration (Figure 2E). We
conclude that the combination therapy creates higher CD8/Treg
ratios than CTLA-4 blockade alone (23:1 versus 11:1, p=0.0002),
while also providing a significantly higher CD4 T-effector/Treg
ratio compared to either a4-1BB alone (2.8:1 versus 2:1, p=0.027)
or to FVAX alone (2.8:1 versus 1.8:1, p=0.0077) which a4-1BB
therapy alone lacks. This combination of both high CD8 and CD4
effector to Treg ratios within the tumor represents the conversion
of the normally suppressive tumor microenvironment to a more
pro-inflammatory state which is more permissive for immune-
mediated tumor rejection.
Figure 2. Combination aCTLA-4/a4-1BB therapy promotes high effector to regulatory T-cell ratios in the tumor. Mice were challenged
with 1.5610
5 B16-BL6, treated with FVAX and the indicated antibody on days 3,6 and 9, and sacrificed on day 15. Percent of CD45+ tumor infiltrating
lymphocytes of A) CD8+ T-cells, B) CD4+ effector (Teff) and C) regulatory (Treg) cells is shown. The ratios of D) CD8+ T-cells to Tregs and E) CD4+ Teff
to Treg are shown. Values shown are for individually analyzed mice and are the sum of 5 independent experiments with 5–15 mice per group. The
ratios of F) CD8+ T-cells to Tregs and G) CD4+ Teff to Treg are shown at Day 25 for individual mice from 2 independent experiments. Student’s t-tests
were performed to determine statistical significance between samples (* - p#0.05, ** - p#0.01, ***-p,0.001).
doi:10.1371/journal.pone.0019499.g002
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difficult to assay tumor infiltrates at later time points than Day-
15, however by using an asymmetric tumor challenge we were
able to ask whether these enhanced effector to regulatory cell
ratios were maintained. Even when the combination treated
mice are given a 10-fold greater tumor challenge than the mice
receiving FVAX alone, high CD8 to Treg ratios are evident at
Day-25 in the groups receiving a4-1BB (Figure 2F). In contrast
to Day-15, the CD4 effector to Treg ratios in the groups
receiving a4-1BB equal those of aCTLA-4 treated mice by
Day-25 (Figure 2G). This could represent the long term effects
of the previously published pro-survival effects of 4-1BB
agonist antibody. In all cases the effector to Treg ratios at
Day-25 are diminished relative to their Day-15 counterparts.
This is likely due to the increased time since the last
vaccination, as well as the reality that all mice with sizable
tumors at Day-25 have failed to respond at a therapeutic level
to the treatment.
The failure of GVAX to support cooperativity between CTLA-
4 blockade and 4-1BB activation does not appear to result from an
inability to generate advantageous effector to Treg ratios.
Although the CD8/Treg ratios generated in the context of GVAX
are slightly lower than those with FVAX (Figure S3A), these
differences do not appear substantial enough to explain the lack
therapeutic synergy. Also, the CD4 effector to Treg ratios
generated following treatment with a4-1BB and either GVAX
or FVAX appear similar (Figure S3B).
Combination aCTLA-4 and a4-1BB therapy increases
inflammatory cytokine production in the vaccine and
tumor draining lymph nodes, as well as in the tumor
itself
To clearly define the functional effects of each therapy on
effector cytokine production, we elected to use the B16-
Ovalbumin (B16-Ova) model antigen system to measure
cytokine responses. Mice were challenged with 2.5610
5 B16-
Ova cells and vaccinated on days 6, 9, and 12 - cytokine
production was analyzed on day 14. While CTLA-4 blockade
did increase IFN-c production from CD8 T-cells in the vaccine
and tumor draining lymph nodes, a4-1BB evoked much
stronger increases in IFN-c,T N F - a, and IL-6 production
(Figure 3A and B). In both nodes it appeared that aCTLA-4 and
a4-1BB co-operated in driving higher levels of TNF-a
production from CD8 T-cells. While we did not observe
changes in TNF-a production from peripheral CD4+ effector
T-cells, there appeared to be a synergistic effect of these two co-
stimulatory modulating agents in promoting high IFN-c
production from CD4 cells in the vaccine draining node
Figure 3. 4-1BB activation cooperates with CTLA-4 blockade to induce peripheral inflammatory cytokine production. Mice
challenged with 2.5610
5 B16-OVA cells and treated on days 6, 9 and 12, were sacrificed on Day 14. T-cells were purified from tumor-draining (TDLN)
and vaccine-draining (VDLN) lymph nodes, stained with antibodies, and sorted by flow cytometry into CD4+ and CD8+ subsets. Cytokine production
was measured after 36 hours using the TH1/TH2/TH17 CBA Kit (BD) and is shown for A) 2610
5 VDLN and B) 2610
5 TDLN CD8 T-cells restimulated on
1610
5 OVA 257–264 peptide pulsed DCs and for C) 2.5610
5 CD4 T-cells restimulated on 1610
5 OVA 323–339 peptide pulsed DCs. Data is shown for
3–4 independent experiments with 5–10 pooled mice per group.
doi:10.1371/journal.pone.0019499.g003
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production from CD4+ T-cells in the tumor draining lymph
node (Figure S4). This .10-fold drop in IFN-c production in
the tumor-draining relative to the vaccine-draining lymph node
suggested that the most active, tumor-specific CD4+ T-cells had
already trafficked into the tumor. Therefore we asked whether
inflammatory cytokine production from the tumor infiltrating
T-cells had been altered by these therapies.
We re-stimulated tumor infiltrating T-cells for 8 hours with
both Ovalbumin and B16 peptide pulsed DCs and measured
intra-cellular cytokine accumulation by flow cytometry (Figure S5).
As in the periphery, a4-1BB promoted the greatest increase in
IFN-c, TNF-a double producing CD8+ T-cells in the tumor
(Figure 4A). It also appeared that CTLA-4 blockade provided a
small additive increase in this population. Both 4-1BB activation
and aCTLA-4 augmented the inflammatory cytokine production
from CD4+ effector T-cells, and their effects were additive when
given in combination (Figure 4B). The combination of co-
stimulatory modulation and FVAX yielded high levels of
inflammatory cytokine production both in the periphery and in
the tumor. We next asked whether these agents had an equally
complementary effect on the proliferation of tumor-infiltrating T-
cells.
Both CTLA-4 blockade and 4-1BB stimulation resulted in
higher CD8+ T-cell proliferation within the tumor as measured by
expression of the cell cycle associated protein Ki-67 (Figure 4C). In
contrast to the CD8 compartment, only CTLA-4 blockade
appeared capable of driving CD4+ effector T-cell proliferation
within the tumor (Figure 4D). Interestingly, a4-1BB appeared to
decrease the proliferation of tumor-infiltrating Tregs, but much of
this effect was lost in combination with CTLA-4 blockade (Figure
S6).
Combination 4-1BB activation and CTLA-4 blockade
induces high expression of KLRG1 and PD-1 on tumor-
infiltrating effector T-cells
We examined co-inhibitory and activation marker expression
on tumor infiltrating T-cells following each therapy in an effort to
gain further mechanistic insight into how these agents promoted
tumor rejection. On tumor infiltrating CD8+ T-cells, there was a
striking upregulation of PD-1 and of the surface receptor KLRG1
in response to both a4-1BB and combination antibody
treatment(Figure 5A). KLRG1 expressing CD8+ T-cells have
been previously described as a terminal effector population
sometimes retained during clearance of viral infections [17].
CTLA-4 expression was increased on CD8+ T-cells in response to
a4-1BB treatment, indicating these cells may have been saved
from co-inhibitory attenuation in the combination therapy group.
Like the CD8 T-cells, the effector CD4+ T-cells infiltrating B16
melanoma expressed much higher levels of KLRG1 and PD-1 in
response to a4-1BB or combination therapy (Figure 5B). In the
CD4+ effector T-cells, however, CTLA-4 expression did not
increase in response to a4-1BB.
Both 4-1BB activation and CTLA-4 blockade decreased CTLA-
4 and PD-1 expression by Tregs in the tumor (Figure 5C). Unlike
Figure 4. Combination aCTLA-4/a4-1BB therapy enhances intra-tumoral T-cell cytokine production and proliferation. Mice
challenged with 2.5610
5 B16-OVA cells and treated on days 6, 9 and 12, were sacrificed on Day 14. TIL were purified from 5–10 pooled tumors per
group and enriched using the Miltenyi T-cell purification kit. 2610
6 TIL were restimulated with 7.5610
5 DC (1:1 mix of MHC-I and MHC-II peptide
pulsed DCs) for 8 hours in the presence of BD GolgiPlug. Cells were fixed using the FoxP3 kit and analyzed by flow cytometry for lymphocyte markers
and intracellular IFN-c and TNF-a production for A) CD8s and B) CD4 Teffs and also Ki67 expression for C) CD8s and D) CD4 Teffs. Data shown is from
4 independent experiments. All means shown are +/2 S.E.M.
doi:10.1371/journal.pone.0019499.g004
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was not significantly elevated in combination treated mice relative
to those receiving FVAX alone.
Given the unique nature of this KLRG1 upregulation, we
assayed whether mice treated with these antibodies in the context
of GVAX rather than FVAX would generate a similar phenotype.
We did observe an enhanced percentage of these KLRG1+
effector T-cells in the tumors of a4-1BB and aCTLA-4/a4-1BB
treated mice receiving GVAX; however, the fraction of KLRG1+
T-cells in both compartments was lower than that generated with
FVAX(Figure S7A and S7B).
The KLRG1+ fraction of tumor infiltrating T-cells increases
in 4-1BB agonist antibody treated mice by Day-25
relative to Day-15
By Day-25 nearly all the CD8+ T-cells and the majority of
CD4+ effector T-cells infiltrating the B16 melanoma tumors of
a4-1BB and a4-1BB/aCTLA-4 treated mice are KLRG1+
(Figure 6A and B). This suggests either selective expansion
and/or recruitment of these cells within the tumor microenvi-
ronment, or establishment of a cytokine environment capable of
converting the majority of tumor infiltrating T-cells to the
KLRG1+ phenotype.
Tumors of mice receiving combination CTLA-4 blockade
and 4-1BB activation are the most highly infiltrated by
KLRG1+CD4+ effector T-cells
The combination of aCTLA-4 and a4-1BB demonstrated
significantly higher therapeutic efficacy than a4-1BB alone
(Figure 1); however, both groups show equally high increases in
the frequency of tumor-infiltrating KLRG1+ T-cells in response
to therapy (Figure 5A&B). By examining the absolute number of
infiltrating KLRG1+ T-cells, however, we found that combina-
tion therapy results in 1.7-fold more CD4+KLRG1+ effector T-
cells per mm
3 of tumor relative to a4-1BB alone (Figure 7). By
contrast, the number of KLRG1+ Tregs between these two
groups was equal.
While in the FVAX background, more KLRG1+ effector T-
cells correlated with superior therapeutic outcome, in the GVAX
setting this was not the case. Although the tumors of mice treated
with GVAX + aCTLA/a4-1BB versus those receiving GVAX +
a4-1BB alone were infiltrated by over 6-fold more KLRG1+
CD8+ and CD4+ effector T-cells, these provided no additional
therapeutic benefit (Figure S8). In contrast to the FVAX setting,
however, the numbers of KLRG1+ Treg cells also increase over 4-
fold in the context of GVAX. This complicates any interpretation
of the potential therapeutic benefit of these KLRG1+ cells in the
Figure 5. Combination aCTLA-4/a4-1BB therapy induces KLRG1 and PD-1 expression by tumor-infiltrating T-cells. Mice challenged
with 1.5610
5 B16-BL6 cells and treated on days 3, 6 and 9, were sacrificed on Day 15. TIL were fixed and stained for lymphocyte lineage and
activation markers using the FoxP3 fixation kit. Percent of A) CD8+ T-cells, B) CD4+ effector (Teff) and C) regulatory (Treg) cells expressing KLRG1, PD-
1, and CTLA-4 are shown. The 4F10 clone of aCTLA-4 was used to detect cells on which CTLA-4 had been blocked in vivo using the 9D9 clone. Values
shown are for individually analyzed mice and are the sum of 4–6 independent experiments with 5–15 mice per group. Student’s t-tests were
performed to determine statistical significance between samples(* - p#0.05, ** - p#0.01, ***-p,0.001).
doi:10.1371/journal.pone.0019499.g005
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described as a highly suppressive one [18].
FVAX promotes more pro-inflammatory ratios of effector
T-cells relative to CD11b+GR-1+ myeloid derived
suppressor cells (MDSC) in antibody-treated mice than
does GVAX
Mice receiving FVAX and both aCTLA-4 and a4-1BB show
enhanced ratios of CD8+ T-cells relative to CD11b+GR-1+
MDSC when compared to either FVAX (3.9 vs. 0.7, p,0.0001) or
aCTLA-4 alone (3.9 vs. 2.2, p=0.03) (Figure 8A). Combination
treated mice also exhibit enhanced ratios of CD4+FoxP3- effector
T-cells relative to MDSC when compared to either FVAX (0.66
vs. 0.38, p=0.02) or a4-1BB alone (0.66 vs. 0.31, p=0.01)
(Figure 8B). Thus, combination treatment with CTLA-4 blockade
and 4-1BB agonist antibody promotes more pro-inflammatory
ratios of CD8+ T-cells to MDSC than aCTLA-4 alone and higher
CD4+ effector T-cell to MDSC ratios than a4-1BB alone.
GVAX has a known capacity to support the generation of
MDSC even when injected on the opposite flank from tumor
implantation [4,19]. We hypothesized that a higher MDSC
density in mice receiving GVAX versus FVAX might be
responsible for the lack of synergy between CTLA-4 blockade
and 4-1BB activation in the GVAX setting. In combination
treated mice we observe both less advantageous CD8+ T-cell to
MDSC ratios (1.4 vs. 6.9) and CD4+FoxP3- effector T-cell to
MDSC ratios (0.24 vs. 0.66) with GVAX versus FVAX
(Figure 8C&D). With GVAX there is also no significant difference
between combination therapy and a4-1BB alone in terms of CD4
effector to MDSC ratio which may contribute to the lack of
therapeutic cooperativity in this setting.
Discussion
Antibodies which activate the T-cell co-stimulatory receptor 4-
1BB or block the co-inhibitory receptor CTLA-4, have demon-
strated broad anti-tumor effects but cannot induce rejection of the
poorly immunogenic B16-BL6 melanoma without the aid of
additional therapeutic interventions [10,14]. In contrast to the
more immunogenic B16-F10 model [14], we show that a4-1BB
mediates few rejection of the highly aggressive B16-BL6
melanoma even in conjunction with GVAX(Figure 1). As we
have observed previously for combination blockade of CTLA-4
and PD-1, we find that co-administration with an autologous
tumor vaccine expressing Flt3-ligand allows these antibodies to co-
operate in rejecting more than 50% of pre-implanted B16-BL6
melanomas [20]. Using this system, we sought to understand the
impact on tumor-specific T-cell responses of simultaneously
removing a major brake on expansion via blockade of the co-
inhibitory receptor CTLA-4, while at the same time actively
driving proliferation and survival through activation of the co-
stimulatory receptor 4-1BB.
Figure 6. High KLRG1 expression by tumor-infiltrating effector T-cells at Day-25 in mice treated with combination aCTLA-4/a4-1BB
therapy. Mice challenged with either 2.5610
4 (Untreated and FVAX), 1.0610
5 (FVAX+aCTLA-4 or a4-1BB), or 2.0610
5 (FVAX+aCTLA-4/a4-1BB) B16-
BL6 cells and treated on days 4, 7 and 10, and 13 were sacrificed on Day 25. TIL were fixed and stained for lymphocyte lineage and activation markers
using the FoxP3 fixation kit. Percent of A) CD8+ T-cells, B) CD4+ effector (Teff) expressing KLRG1 are shown. Values shown are for individually
analyzed mice and are the sum of 2 independent experiments with 10 mice per group. Student’s t-tests were performed to determine statistical
significance between samples(* - p#0.05, ** - p#0.01, ***-p,0.001).
doi:10.1371/journal.pone.0019499.g006
Figure 7. Combination aCTLA-4/a4-1BB therapy induces higher
tumor infiltration by CD4+KLRG1+ T-cells than a4-1BB alone.
Mice challenged with 1.5610
5 B16-BL6 cells and treated on days 3, 6
and 9, were sacrificed on Day 15. The number of KLRG1+ T-cells of a
given lineage was calculated by multiplying the %KLRG1+ TIL
determined by flow cytometry by the measured number of CD45+
lymphocytes per mm
3 of tumor. Data shown are ratios of the absolute
number of KLRG1+ T-cells from combination treated tumors to the
number of KLRG1+ T-cells from a4-1BB alone treated tumors. Ratios
were calculated for 5 independent experiments with 5–15 mice per
group.
doi:10.1371/journal.pone.0019499.g007
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cells and for this reason most tumor immunity studies have focused
on the impact of a4-1BB on this subset [6]. We found that 4-1BB
activation promoted much stronger CD8 infiltration of tumors
(Figure 2), inflammatory cytokine production by peripheral CD8
cells (Figure 3), and proliferation of tumor infiltrating CD8s
(Figure 4). While CD4 effector infiltration and proliferation were
only increased by CTLA-4 blockade (Figure 4), a4-1BB did
increase inflammatory cytokine production from these cells both in
the periphery and within the tumor itself. The mechanisms
underlying this uncoupling of the proliferative and TH1 cytokine
promoting effects of 4-1BB agonist antibody treatment in CD4
versus CD8 cells are of interest to us and will be addressed in
future studies.
The activation of CD8 T-cells by a4-1BB coupled with the
expansion of CD4 effector T-cells by aCTLA-4 clearly accounts
for some of the observed synergy between these agents in rejecting
B16 melanomas. 4-1BB activation has been described as a
powerful promoter of TH1-type cytokine production [6,21,22].
In prior studies using the B16-Ova model, we have observed a
tendency of co-inhibitory blockade to increase TH2 responses in
the vaccine draining lymph node [20]. In this case, however, a4-
1BB polarized cytokine production to TH1 and induced TNF-a
production by CD8 T-cells and IFN-c production by CD4 cells to
levels that exceeded the sum of each individual therapy (Figure 3).
Similarly, combination therapy additively increased the percent-
age of IFN-c,TNF-a double producing CD4+ effectors in the
tumor (Figure 4). A portion of the anti-tumor effect of CTLA-4
blockade derives from inhibition of Tregs [23]; however, the
effects of a4-1BB on Treg proliferation and suppression remain
unclear [8,9,10,11]. Here, a4-1BB dampened Treg proliferation
(Figure S6), reduced the Treg fraction of TIL (Figure 2),
counteracted aCTLA-4’s expansion of absolute Treg numbers in
the tumor (Figure S2), and decreased CTLA-4 and PD-1
expression by Tregs (Figure 5). We conclude that at least a
portion of the benefit of combination co-stimulatory modulation is
due to reduction of Treg suppression in the tumor.
Distinct from other co-stimulatory antibodies, we found that a4-
1BB induced striking upregulation of KLRG1 on CD8+, and to a
lesser degree CD4+, effector T-cells in the tumor (Figure 5 and 6).
This KLRG1 upregulation appeared unique to 4-1BB agonist
antibody, as we did not observe a similar phenotype in response to
aCTLA-4 (Figure 5), aPD-1, or aPD-L1 (Figure S9). We found
that mice receiving the therapeutically more effective aCTLA-4/
a4-1BB combination therapy had 1.7-fold more CD4+KLRG1+
cells infiltrating their tumors relative to mice treated with a4-1BB
alone (Figure 7), suggesting a possible functional significance to
this population. In addition, the KLRG1+ fraction of TIL seemed
to increase over time for both CD8+ and CD4+ effector T-cells
suggesting either enhanced infiltration, survival, or proliferation of
Figure 8. Combination aCTLA-4/a4-1BB treatment generates more pro-inflammatory ratios of effector T-cells to MDSC in the
context of FVAX versus GVAX. Mice challenged with 1.5610
5 B16-BL6 cells and treated on days 3, 6 and 9, were sacrificed on Day 15. TIL were
fixed and stained for myeloid and lymphocyte lineage and activation markers using the FoxP3 fixation kit. The ratios of A) CD8+ T-cells to CD11b+GR-
1+ MDSC and B) CD4+ Teff to MDSC are shown in the FVAX setting. Values shown are for individually analyzed mice and are the sum of 3
independent experiments with 5–15 mice per group. The ratios of C) CD8+ T-cells to MDSC and D) CD4+ effector T-cells to MDSC are shown in the
context of GVAX for 10 individual mice per group. Student’s t-tests were performed to determine statistical significance between samples (* - p#0.05,
** - p#0.01, ***-p,0.001).
doi:10.1371/journal.pone.0019499.g008
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infiltrating T-cells and their contribution to tumor rejection is of
intense interest to us and will be the focus of future study.
The co-inhibitory receptor PD-1 which we have previously
shown to be induced on T-cells following CTLA-4 blockade [20],
also appears highly induced by 4-1BB activation (Figure 5A and
B). Like CTLA-4, PD-1 can attenuate effector T-cell proliferation
and effector function, causing anti-tumor immune responses to
fail. The data presented here suggests that combining antibody
blockade of PD-1 or both CTLA-4 and PD-1 with activation of 4-
1BB may provide substantial benefit to auto-tumor immune
responses.
Although our focus was on understanding the mechanisms
underlying the therapeutic efficacy of combination aCTLA-4/
a4-1BB treatment in the context of FVAX, we did explore
potential reasons for the failure of GVAX to support synergy
between these antibodies (Figure 1). While ratios of CD8 T-cells
to Tregs within tumors of treated mice were slightly lower in the
context of GVAX versus FVAX, the overall pattern of CD8 and
CD4 effector T-cell to Treg ratios was similar in both treatment
settings (Figure S3). Combination therapy generated higher
fractions of both KLRG1+ CD8+ and CD4+ effector T-cells in
the context of FVAX versus GVAX which may be significant in
explaining the lack of cooperativity observed with GVAX (Figure
S7). Also, it appeared that with GVAX the fraction of KLRG1+
CD4+ FoxP3- cells might be reduced in the combination treated
mice relative to the mice receiving a4-1BB alone (mean of 31%
vs. 23%); however, the magnitude of this difference did not reach
statistical significance for the number of mice analyzed. We also
found that although the numbers of KLRG1+ effectors per mm3
of tumor were higher with combination treatment versus a4-1BB
alone, the numbers of highly-suppressive KLRG1+ Tregs were
also increased (Figure S8). In addition to this increase of
KLRG1+ Treg cells, we found far less advantageous effector T-
cell to MDSC ratios in the tumors of mice treated with GVAX as
opposed to FVAX (Figure 8). Also, the higher CD4+ to MDSC
ratios observed with FVAX and aCTLA-4/a4-1BB versus a4-
1BB alone were not evident in the context of GVAX. This
increased suppressive burden in the context of GVAX versus
FVAX could be reducing the fraction of tumor-infiltrating
effector T-cells which develop into optimal effectors as well as
reducing the cooperative augmentation of effector function we
observe with FVAX.
Blockade of the co-inhibitory receptor CTLA-4 in the clinic has
shown promise as a therapy for advanced solid tumors, however
immune related adverse events associated with this treatment can
be quite severe [24]. The major side of effect of 4-1BB agonist
antibody treatment, at least in mice, appears to be an as yet poorly
mechanistically defined inflammatory liver toxicity [10]. Interest-
ingly, it has been reported in a pre-clinical model that aCTLA-4
and a4-1BB each reduced the auto-reactive side effects of the
other [10]. Taken with our data showing strong cooperativity
between these agents in rejecting B16-BL6 melanoma, further
studies are certainly warranted to assess the safety of using 4-1BB
agonist antibody and CTLA-4 blockade in combination.
Materials and Methods
Mice
All mouse procedures were performed in accordance with
institutional protocol guidelines at Memorial Sloan-Kettering
Cancer Center (MSKCC). Mice were maintained according to
NIH Animal Care guidelines, under a protocol 04-07-019
approved by the MSKCC Institutional Animal Care Committee.
C57BL/6 Mice (4–6 week old males) were obtained from Jackson
Labs. B6.SJL mice (6 week old male) were obtained from Taconic.
Antibodies
Anti-CTLA-4 (9D9), a4-1BB (LOB12.3) [12], Rat Ig and
mIgG2b used in vivo were produced by Bioxcell. Dosing per
injection was 100 ug 9D9, 350 ug LOB12.3, 350 ug RatIg, and
100 ug mIgG2b.
Staining antibodies included CD4-Q605, CD8-Pacific Orange,
CD3-APCAlexa750 - Invitrogen. CD4-APC, FoxP3 Pacific Blue,
KLRG1-APC, PD-1-FITC, 4-1BB-biotin - eBioscience. CD8-PE,
IFN-c-PE-CY7, Ki67-FITC, TNFa-APC - BD Bioscience. ICOS,
CTLA-4 (4F10) - Bioxcell. CD45.1 PerCP - Biolegend. Some
clones were conjugated using Invitrogen monoclonal antibody
conjugation kits to either Alexa 532, Alexa 594, or Qdot 655.
Cell Lines
B16/BL6 cells as well as B16-sFlt3L-Ig (FVAX) and B16-
GMCSF (GVAX) have been described previously [4].
Peptides
Ovalbumin 257–264 (SIINFEKL) and 323–339 (ISQAVHAA-
HAFINEAGR) (American Peptide Company) were used at a final
concentration of 5 uM. GP100 (25), Trp-1 (455, 481, and 522),
and Trp-2 (181) peptides used for re-stimulation of TIL were
obtained from Biosynthesis Inc. and used at 10 uM final.
B16 Melanoma Treatment Experiments
Mice were injected in the flank i.d. at day 0 with 2.5610
4 B16-
BL6 cells and treated on days 3, 6, and 9 respectively with 1610
6
irradiated (150 Gy) gene-modified B16 cells on the contralateral
flank and the indicated therapeutic antibody intra-peritoneally.
Tumor Infiltration/Activation Marker Analysis
Mice receiving a 1.5610
5 B16-BL6 challenge were vaccinated
as above on days 3,6, and 9 and sacrificied on Day 15. For Day-25
experiments, untreated and FVAX-treated mice received 2.5610
4
B16-BL6 cells, aCTLA-4 and a4-1BB treated mice received
1610
5 B16 cells, and combination treated mice received 2610
5
B16 cells with vaccination on days 4,7,10, and 13. Tumors were
measured immediately prior to sacrifice. Excised tumors were
digested in Liberase (Roche) and DNAase (Roche), cells were
counted, and lymphocytes were enriched on a ficoll gradient
(Sigma Histopaque 1119). Cells were stained using the eBioscience
FoxP3 staining kit – CTLA-4 and PD-1 were stained for total
intra- and extra-cellular protein. Stained samples were run
completely on an LSRII (BD Bioscience) cytometer.
Analysis of Cytokine Production
Mice receiving a 2.5610
5 B16-Ovalbumin challenge in 30%
Matrigel (BD Bioscience) were vaccinated as above on days 6, 9
and 12 and sacrificied on Day 14. Vaccine and tumor draining
lymph nodes as well as tumors were pooled from 5 mice per group.
Lymph node cells were stained with DAPI and antibodies to CD4
and CD8 and sorted on a MoFlo cell sorter (Beckman Coulter).
Tumor cells were purified as above except that prior to
restimulation the T-cell fraction was enriched using a Miltenyi
T-cell purification kit. 2610
5 CD8 cells and 2.5610
5 CD4 cells
per well were restimulated in 96-well round bottom plates with
1610
5 Ovalbumin peptide pulsed DCs purified from B6.SJL
spleens using CD11c positive selection beads (Miltenyi) for
36 hours and then cytokine production was assessed using the
TH1/TH2/TH17 CBA kit from BD Bioscience. For tumor
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6 T-enriched TIL were re-stimulated with 7.5610
5
Ovalbumin and B16 melanoma peptide-pulsed DCs for 8 hours in
the presence of GolgiPlug (BD Bioscience) and then fixed and
stained for intra-cellular cytokine production using the eBioscience
FoxP3 kit.
Supporting Information
Figure S1 Anti-CTLA-4 and a4-1BB antibodies alone do
not cure B16-BL6. Kaplan-Meier survival curves for mice
challenged with 2.5610
4 B16-BL6 cells and vaccinated on days 3,
6 and 9 with the indicated antibody combination intra-
peritoneally. Lack of survival was defined as death or tumor size
.1000 mm
3. Each curve represents 3 independent experiments of
5 mice per group. P values were calculated using the Log-rank
(Mantel-Cox) test (* - p#0.05, ** - p#0.01, ***-p,0.001).
(TIF)
Figure S2 Combination aCTLA-4/a4-1BB therapy
drives high absolute numbers of CD4 and CD8 effectors
to infiltrate tumors. Mice were challenged with 1.5610
5 B16-
BL6, treated with FVAX and the indicated antibody on days 3,6
and 9, and sacrificed on day 15. Number of lymphocytes per mm
3
of tumor shown for A) CD8+ T-cells, B) CD4+ effector (Teff) and
C) regulatory (Treg) cells. Values shown are for individually
analyzed mice and are the sum of 5 independent experiments with
5–15 mice per group. Student’s t-tests were performed to
determine statistical significance between samples (* - p#0.05,
** - p#0.01, ***-p,0.001).
(TIF)
Figure S3 Combination aCTLA-4/a4-1BB therapy pro-
motes similar effector to regulatory T-cell ratios in the
tumors of mice receiving GVAX compared to FVAX. Mice
challenged with 1.5610
5 B16-BL6 cells and treated on days 3, 6
and 9, were sacrificed on Day 15. TIL were fixed and stained for
lymphocyte lineage and activation markers using the FoxP3
fixation kit. The ratios of A) CD8+ T-cells to Tregs and B) CD4+
Teff to Tregs are shown in the GVAX setting with means shown
as green bars and with FVAX means shown in red for comparison.
Values shown are for 10 individual mice per group.
(TIF)
Figure S4 Combination aCTLA-4/a4-1BB increases T-
cell IFN-c production in tumor draining lymph node.
Mice challenged with 2.5610
5 B16-OVA cells and treated on
days 6, 9 and 12, were sacrificed on Day 14. T-cells were
purified from tumor-draining (TDLN), stained with antibodies,
a n ds o r t e db yf l o wc y t o m e t r yi n t oC D 4 + and CD8+ subsets.
Cytokine production was measured after 36 hours using the
TH1/TH2/TH17 CBA Kit (BD) and is shown for 2610
5
TDLN CD8 T-cells restimulated on 1610
5 OVA 257–264
peptide pulsed DCs.
(TIF)
Figure S5 Flow cytometry gating of tumor-infiltrating
lymphocytes for cytokine production and proliferation.
Mice challenged with 2.5610
5 B16-OVA cells and treated on days
6,9 and 12, were sacrificed on Day 14. TIL were purified from 5–
10 pooled tumors per group and enriched using the Miltenyi T-
cell purification kit. 2610
6 TIL were restimulated with 7.5610
5
peptide-pulsed DC for 8 hours in the presence of BD GolgiPlug.
Cells were fixed using the FoxP3 kit and analyzed by flow
cytometry for lymphocyte markers, intracellular IFN-c and TNF-a
production, and Ki67 expression. Representative data is shown
from one experiment to illustrate the gating and controls used to
derive the data in Figure 4.
(TIF)
Figure S6 4-1BB agonist antibody treatment reduces
intra-tumoral FoxP3+ Treg proliferation. Mice challenged
with 2.5610
5 B16-OVA cells and treated on days 6, 9 and 12,
were sacrificed on Day 14. TIL were purified from 5–10 pooled
tumors per group and enriched using the Miltenyi T-cell
purification kit. 2610
6 TIL were restimulated with 7.5610
5
peptide-pulsed DC for 8 hours in the presence of BD GolgiPlug.
Cells were fixed using the FoxP3 kit and analyzed by flow
cytometry for lymphocyte markers. Data shown is from 4
independent experiments for CD4+FoxP3+ Tregs. All means
shown are +/2 S.E.M.
(TIF)
Figure S7 Combination aCTLA-4/a4-1BB therapy in-
duces a higher fraction of CD8+ and CD4+ effector T-
cells to become KLRG1+ with FVAX compared to GVAX.
Mice challenged with 1.5610
5 B16-BL6 cells and treated on days
3, 6 and 9, were sacrificed on Day 15. TIL were fixed and stained
for lymphocyte lineage and activation markers using the FoxP3
fixation kit. The percentages of tumor-infiltrating A) CD8+ T-cells
and B) CD4+ effector T-cells positive for KLRG1 are shown in the
GVAX setting with means shown as green bars and with FVAX
means shown in red for comparison. Values shown are for 10
individual mice per group.
(TIF)
Figure S8 Combination aCTLA-4/a4-1BB therapy with
GVAX induces higher tumor infiltration by both effector
and regulatory KLRG1+ T-cells than a4-1BB alone. Mice
challenged with 1.5610
5 B16-BL6 cells and treated on days 3, 6
and 9, were sacrificed on Day 15. The number of KLRG1+ T-
cells of a given lineage was calculated by multiplying the
%KLRG1+ TIL determined by flow cytometry by the measured
number of CD45+ lymphocytes per mm
3 of tumor. Data shown
are ratio of the absolute number of KLRG1+ T-cells from 10
combination treated tumors to the number of KLRG1+ T-cells
from 10 a4-1BB alone treated tumors.
(TIF)
Figure S9 Antibodies which block PD-1 or PD-L1 do
not induce high levels of KLRG1 expression by tumor-
infiltrating T-cells. Mice challenged with 1.5610
5 B16-BL6
cells and treated on days 3, 6 and 9, were sacrificed on Day 15.
TIL were fixed and stained for lymphocyte lineage and
activation markers using the FoxP3 fixation kit. Percent of A)
CD8+ T-cells, B) CD4+ effector (Teff) cells expressing KLRG1
are shown. Values shown are for individually analyzed mice and
are the sum of 4–6 independent experiments with 5–15 mice per
group. Student’s t-tests were performed to determine statistical
significance between samples(* - p#0.05, ** - p#0.01, ***-
p,0.001).
(TIF)
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